

The impact of intense nursing care in improving anxiety, depression, and quality of life in patients with liver cancer

A systematic review and meta-analysis

Qiao Zhang, RN^a, Rong Wan, RN^b, Changdan Liu, RN^{a,*}

Abstract

Background: Liver resection is a major, serious, and very delicate operation that should be done only by specialized, well-skilled, and experienced surgeons. However, the role of nurses, which has often been under-estimated, is also crucial for the success of the intervention or surgery. Intensive nursing care involves high quality nursing modes to achieve the expected goals of treatment smoothly and with less complications. In this analysis, we aimed to show the impact of intense nursing care in improving anxiety, depression, and quality of life in patients with intervention for liver cancers.

Methods: Data sources included EMBASE, MEDLINE, Web of Science, the Cochrane central, Google scholar, and http://www. ClinicalTrials.gov. Three authors independently extracted data from the selected original studies. The statistical analysis was carried out by the Cochrane based RevMan software. For dichotomous data, the number of events and the total number of participants were required and for the continuous data, mean, standard deviation as well as the total number of participants were required in the input for analysis. Odds ratios (OR) with 95% confidence intervals (CI) were used to represent the data following assessment.

Results: A total of 1205 participants with liver cancer enrolled between the years 2010 to 2018 were included in this analysis whereby 667 participants were assigned to an intensive nursing care. Our current analysis showed that most of the patients who were assigned to an intense nursing intervention were significantly very satisfied with their quality of life (OR: 4.07, 95% CI: 1.45 – 11.45; P=.008). However, a minor number of patients with liver cancer who were not assigned to intense nursing care were significantly dissatisfied with their quality of life with OR: 0.18, 95% CI: 0.04 – 0.77; P=.02. This analysis also showed that self-rating anxiety score (SAS) and self-rating depression score (SDS) were significantly in favor of the participants with intense nursing care with OR: -7.66, 95% CI: [(-9.66) - (-5.66)]; P=.00001 and OR: -7.87, 95% CI: [(-8.43) - (-7.26)]; P=.00001 respectively. In addition, physical function (OR: 13.56, 95% CI: 12.39 – 14.74; P=.00001), and total activity score (OR: 16.58, 95% CI: 13.51 – 19.65; P=.00001) were also significantly in favor of an intense nursing care.

Conclusions: Our current analysis showed that intense nursing care significantly improved anxiety, depression, and quality of life following interventions in patients with liver cancers. Most of the patients with liver cancers who were assigned to an intense nursing care were very satisfied with their quality of life. However, this hypothesis should further be confirmed in larger nursing related studies based on patients with liver cancers.

Abbreviations: CI = confidence intervals, HCC = hepatocellular carcinoma, INC = intense nursing care, OR = odds ratios, QOL = quality of life, SAS = Self Rating Anxiety Scale, SDS = Self Rating Depression Scale.

Keywords: anxiety, depression, intense nursing care, liver cancers, quality of life, self rating anxiety scale, self rating depression scale

Editor: Massimo Tusconi.

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

Received: 29 March 2020 / Received in final form: 7 July 2020 / Accepted: 10 July 2020

http://dx.doi.org/10.1097/MD.000000000021677

QZ and RW contributed equally to this work and are the first co-authors.

Ethical approval was not applicable for this systematic review and meta-analysis.

The authors have no funding and conflicts of interest to disclose.

All data and materials used in this research are freely available in electronic databases (EMBASE, MEDLINE, Web of science, Cochrane database, Google scholar and http://www.ClinicalTrials.gov). References have been provided.

The datasets generated during and/or analyzed during the current study are publicly available.

^a Department of Hepatobiliary Surgery, ^b Department of Midwifery, Jingzhou Central Hospital, Jingzhou, Hubei, China.

^{*} Correspondence: Changdan Liu, Department of Hepatobiliary Surgery, Jingzhou Central Hospital, Jingzhou, Hubei, China (e-mail: liuchangdan88@163.com).

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Zhang Q, Wan R, Liu C. The impact of intense nursing care in improving anxiety, depression, and quality of life in patients with liver cancer: a systematic review and meta-analysis. Medicine 2020;99:34(e21677).

1. Introduction

Liver carcinoma is rapidly increasing in this new era with the increasing number of chronic hepatitis and liver cirrhosis. Statistics show that liver cancer accounts for about 42% of all cancers in China, and the number is rising drastically with approximately 600,000 new cases and 200,000 deaths annually.^[1] Hepatic surgeries and liver transplantations are the best options till date to treat liver cancers.^[2] According to the Organ Procurement and Transplantation Network, about 1000 liver transplantations have been done in the United States in 2016.^[3] However, whatever the treatment option, the decision should produce satisfactory outcomes in terms of survival and recurrence. For hepatocellular carcinoma patients whose tumors have successfully been resected, the 5-year survival rate lies between 10% to 60% depending on the type and size of the mass. The main goal of liver resection is to completely remove the tumor and the associated surrounding liver tissues with minimal residue and without inducing hepatic failure. However, in practice, because of these strict guidelines, only selected patients with liver cancer can undergo liver resection.^[4]

Liver resection is a major, serious, and very delicate operation that should be done only by specialized, well-skilled, and experienced surgeons.^[5] However, this surgery also requires skillful and specialized nurses. The role of nurses have often been under-estimated and left unnoticed through research. It should be noted that intense care by nurses postoperatively has contributed immensely in the complete success of many surgeries.^[6] Patients are often anxious, depressed following hepatic surgeries, therefore psychological, and moral support are vital post-operatively to further improve the quality of life of these patients.

Intensive nursing care^[7] which has been defined as nursing care with additional caring facilities and methods including group nursing whereby several nurses are assigned to 1 particular patients, with combined nursing measures such as nursing plan, nursing philosophy, and nursing quality evaluation and which involves high quality nursing modes to achieve the expected goals of treatment smoothly and with less complications, should be implemented for these patients with intervention for liver cancers.

In this analysis, we aimed to show the impact of intense nursing care in improving anxiety, depression, and quality of life in patients with intervention for liver cancers.

2. Methods

2.1. Data sources and search strategies

Data sources included EMBASE, MEDLINE, Web of Science, the Cochrane central, Google scholar, and http://www.Clinical Trials.gov.

Publications were searched using the following key terms:

- Nursing care and liver cancer;
- Nurse practice and liver disease;
- Nursing care and liver disease;
- Nurse intervention and liver cancer;
- Nurse intervention and liver surgery;
- Nurse intervention and hepatobilliary;

The term "liver" was also replaced by the word "hepatic" and the word "cancer" was substituted by "tumor"/"carcinoma".

2.2. Inclusion and exclusion criteria

Studies were included if:

- (a) They were trials or observational cohorts comparing participants with liver cancers who were assigned to an intense nursing care versus a control group;
- (b) They reported potentially relevant endpoints including outcomes related to anxiety, depression, and quality of life;
- (c) They were published in English language.

Studies were excluded if:

- (a) They were review articles including meta-analysis/systematic reviews and literature reviews;
- (b) They did not involve participants with liver cancers;
- (c) They did not report the potentially relevant outcomes;
- (d) They did not involve intense nursing care;
- (e) They were duplicated studies which were repeated in different searched databases.

2.3. Definitions and Outcomes

Intensive nursing care has been defined as nursing care with additional caring facilities and methods including group nursing whereby several nurses are assigned to 1 particular patient, with combined nursing measures such as nursing plan, nursing philosophy, and nursing quality evaluation. It also involves high quality nursing modes to achieve the expected goals of treatment smoothly and with less complications.

Table 1 listed the endpoints which were reported in the original studies.

The final list of outcomes which were assessed in this metaanalysis was:

- (a) Quality of life (including very satisfied, satisfied, and dissatisfied);
- (b) Self-rating anxiety scale (SAS);
- (c) Self-rating depression scale (SDS);
- (d) Physical function;
- (e) Total activity score;
- (f) Social function.

2.4. Data extraction and quality assessment

Three authors independently extracted data from the selected original studies. The total number of participants with liver cancer who were assigned to intense nursing care and conventional nursing care were respectively extracted from each original studies. The total number of participants reporting their satisfaction with intense nursing care, the mean and standard deviation associated with SAS, SDS, physical function, total activity score, and social function were also carefully extracted to be used in the analysis. The time period of participants' enrollment, the type of study, the year of publication, and the baseline features of the participants were also carefully extracted. Any disagreement which occurred during the data extraction process was resolved by a discussion with the corresponding author.

Two methodological assessment tools including the Cochrane collaboration^[13] for randomized trials and the Newcastle Ottawa scale (NOS)^[14] for observational studies were used for the quality assessment. Grades ranging from A to C were allotted to the studies, whereby a grade A denoted a low bias risk and a grade C denoted a high bias risk.

Studies	Outcomes
Gou 2019 ^[8]	Very satisfied, satisfied, not satisfied, quality of life average score, physical function, cognitive function, emotional function, function of social activities, no pains, survival rate
Ji 2020 ^[9]	Appetite, sleep quality, length of stay, SAS, SDS, quality of life, physical score, emotional function, role function, social function, very satisfied, satisfied dissatisfied, nursing satisfaction
Li 2018 ^[10]	Hospitalization time, SAS score, SDS score, quality of life score
Luan 2020 ^[11]	Physiological function, mental function, social function, total quality of life score, SAS score, SDS score
Pang 2019 ^[12]	Daily activity score, SDS score, SAS score, very satisfied, satisfied, dissatisfied

SAS = Self Rating Anxiety Scale, SDS = Self Rating Depression Scale.

2.5. Statistical analysis

The statistical analysis was carried out by the Cochrane based RevMan software (Version 5.3).

For dichotomous data, the number of events and the total number of participants were required.

For the continuous data, the mean, standard deviation as well as the total number of participants were required in the input for analysis.

Odds ratios (OR) with 95% confidence intervals (CI) were used to represent the data following assessment by RevMan software.

The assessment of heterogeneity was carried out by the Q statistic test whereby a particular subgroup analysis showed a statistically significant result if the corresponding P value was less or equal to .05.

Assessment of heterogeneity was also done by observing the I^2 value. The range of I^2 value was reported to be between 0% to 100%. Heterogeneity increased with an increasing I^2 value.

In this analysis, a random effects statistical model was used during assessment of the subgroups.

An exclusion method whereby each study was excluded one by one and a new analysis was carried out each time, was used for sensitivity analysis.

Publication bias was visually assessed through asymmetry of funnel plots which were generated through the RevMan software.

2.6. Ethical approval

This study is a meta-analysis and included data from previously published original studies. No experiment was carried out on animals or human beings by any of the authors. Therefore, an ethical approval was not required.

3. Results

3.1. Results of the search process

We followed the PRISMA reporting guideline for the search process.^[15] A total number of 958 articles were found through online databases. An initial assessment was carried out by the authors after having studied the titles and abstracts. Following this initial assessment, 897 articles were eliminated since they were not related to the topic of this research article. Sixty-one full text articles were assessed for eligibility. However, further elimination was carried out for the following reasons: review articles (6); case studies (7); did not involve intense nursing care (12); published in a different language apart from English (3); did not report the relevant outcomes (3); repeated studies (25). Finally, only 5 studies [8–12] were selected for this analysis as shown in Figure 1.

3.2. Main features of the selected studies

The main features of the original selected studies have been given in Table 2. Four studies were observational studies whereas 1 study was a randomized trial. A total of 1205 participants with liver cancer were included in this analysis whereby 667 participants were assigned to an intensive nursing care and 538 participants were assigned to a conventional nursing care as shown in Table 2. The time period of participants' enrollment ranged from the year 2010 to year 2018.

After a methodological assessment of the studies, 1 study was allotted a grade C whereas the remaining 4 studies were allotted a grade B implying moderate bias risk as shown in Table 2.

3.3. Baseline features of the participants

The baseline features of the participants have been listed in Table 3. The mean age of the participants was 50.1 to 58.8 years. Male participants ranged from 54.76% to 87.13%. The percentage of patients who were smokers ranged from 47.62% to 70.0% as shown in Table 3.

3.4. Results of this analysis

Our current analysis showed that most of the patients who were assigned to an intense nursing intervention were significantly very satisfied with their quality of life (OR: 4.07, 95% CI: 1.45 – 11.45; P = .008) as shown in Figure 2. A minority of participants who were not assigned to an intensive nursing care was still satisfied with their quality of life (OR: 0.44, 95% CI: 0.13 – 1.51; P = .19). However, participants who were not assigned to intense nursing care were significantly dissatisfied with their quality of life (OR: 0.18, 95% CI: 0.04 – 0.77; P = .02) as shown in Figure 2.

This analysis also showed that SAS and SDS were significantly in favor of the participants with intense nursing care with OR: -7.66, 95% CI: [(-9.66) - (-5.66)]; P = .00001 and OR: -7.87,95% CI: [(-8.43) - (-7.26)]; P = .00001 respectively as shown in Figure 3.

In addition, physical function (OR: 13.56, 95% CI: 12.39 – 14.74; P=.00001), and total activity score (OR: 16.58, 95% CI: 13.51 – 19.65; P=.00001) were also significantly in favor of an intense nursing care as shown in Figure 4. However, even if social function (OR: 10.84, 95% CI: -2.83 – 24.51; P=.12) was also in favor of an intense nursing care in these patients with liver cancer, the result did not reach statistical significance.

Sensitivity analysis showed consistency throughout and publication bias was represented in Figure 5.




Figure 1. Flow diagram representing the study selection.

4. Discussion

Our results showed that intense nursing care in these patients with liver cancer significantly improved quality of life since many participants expressed their significant satisfaction. However, a minority of patients were dissatisfied among those who did not receive intensive nursing care following intervention for liver cancer. Results of this analysis also showed significantly higher rate of anxiety and depression among those patients who did not receive intense nursing care following intervention for liver cancer. Physical function and total activity score was also

Studies	Type of study	Participants' enrollment time period	No of participants without intense nursing care (n)	No of participants with intense nursing care (n)
Gou2019	OS (B)	2010 - 2016	202	310
Ji2020	OS (B)	_	42	42
Li2018	RT (C)	2015 – 2017	52	52
Luan2020	OS (B)	2014 - 2018	200	200
Pang2019	OS (B)	2010 - 2012	42	63
Total no of participants (n)			538	667

OS = observational studies, RT = randomized trial.

Table 3

Baseline features of the studies.

Studies	Age (yr) INI/NNI	Males (%) INI/NNI	Smoking (%) INI/NNI	TNM staging INI/NNI
Gou2019	51.32/52.14	84.52/87.13	70.0/67.82	50.0/50.0
Ji2020	58.8/56.3	54.76/61.9	54.76/64.29	-
Li2018	58.46/58.38	59.6/57.6	_	-
Luan2020	_	_	_	-
Pang2019	51.2/50.1	60.32/59.52	55.56/47.62	-

INI = intense nursing intervention, NNI = no intense nursing intervention, TNM = tumor staging.

11.1 / Pary satisfied with Quality of Life Gou2019 256 310 67 202 11.7% 9.55 [6.31, 14.46] j_{2020} 24 42 15 42 11.2% 2.40 [1.00, 5.78] Pang2019 35 63 14 42 11.3% 2.50 [1.11, 5.63] Subtotal (95% CI) 415 286 34.2% 4.07 [1.45, 11.45] Total events 315 96 Heterogeneity: Tau ² = 0.70; Ch ² = 13.47, df = 2 (P = 0.001); P = 85% Test for overall effect: $Z = 2.66 (P = 0.008)$ 11.2 Satisfied with Quality of Life Gou2019 52 310 113 202 11.7% 0.16 [0.11, 0.24] J02020 15 42 13 42 11.2% 1.24 [0.50, 3.08] Pang2019 22 63 22 42 11.3% 0.49 [0.22, 1.08] Subtotal (95% CI) 415 2286 34.2% 0.44 [0.13, 1.51] Total events 89 148 Heterogeneily: Tau ² = 1.07; Ch ² = 19.39, df = 2 (P < 0.0001); P = 90% Test for overall effect: $Z = 1.31 (P = 0.19)$ 11.3 Dissatisfied with Quality of Life Gou2019 2 310 22 202 10.3% 0.05 [0.01, 0.23] J2020 3 42 14 42 10.5% 0.15 [0.04, 0.59] Gou2019 2 310 22 202 10.3% 0.05 [0.01, 0.23] J2020 3 42 14 42 10.7% 0.63 [0.19, 2.11] Subtotal (95% CI) 415 286 31.6% 0.18 [0.04, 0.57] Total events 11 42 Heterogeneity: Tau ² = 1.18; Ch ² = 7.11, df = 2 (P = 0.0001); P = 96% Test for overall effect: $Z = 2.31 (P = 0.02)$ Total events 415 286 Heterogeneity: Tau ² = 1.6P = 7.11, df = 2 (P = 0.00001); P = 96% Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect: $Z = 0.53 (P = 0.60)$ Test for overall effect:		Int Nursing Interv	vention	No Int Nursing			Odds Ratio	Odds Ratio	Risk of Bias
Gau201 ¹ 256 310 67 202 11.7% 9.55 [6.31, 14.48] 30200 24 42 15 42 11.3% 2.40 [10.0, 5.78] Pang2019 35 43 14 42 11.3% 2.40 [10.0, 5.78] Pang2019 35 415 96 34.2% 4.07 [1.45, 11.45] Subotal (95% CI) 315 96 Heterogeneity: Tau" = 0.70; Chi" = 13.47, df = 2 (P = 0.001); P = 85% Tast for overall effect: $2 = 2.6 (P = 0.001); P = 85\%$ Tast for overall effect: $2 = 2.6 (P = 0.001); P = 85\%$ Tast for overall effect: $2 = 2.6 (P = 0.001); P = 85\%$ Tast for overall effect: $2 = 2.6 (P = 0.001); P = 90\%$ Heterogeneity: Tau" = 1.07; Chi" = 13.93, df = 2 (P = 0.001); P = 90\% Tast for overall effect: $2 = 1.31 (P = 0.19)$ 1.1.3 Disatisfied with Quality of Life Gou2019 2 3 10 22 202 10.3% 0.05 [0.01, 0.23] J0202 3 42 14 42 10.5% 0.05 [0.01, 0.23] J0202 415 286 31.6% 0.16 [0.01, 0.24] J0202 3 42 14 42 10.5% 0.05 [0.01, 0.23] J0202 3 42 14 42 10.5% 0.05 [0.01, 0.23] J0202 3 42 14 42 10.5% 0.05 [0.01, 0.23] J0202 3 42 14 42 10.5% 0.05 [0.01, 0.21] J0202 3 415 286 31.6% 0.16 [0.04, 0.57] Total events 11 42 Subtotal (95% CI) 415 286 31.6% 0.18 [0.04, 0.77] Total events 11 42 Total events 11 42 Total events 11 9 42 J0205 415 286 $J00.0%$ 0.70 [0.19, 2.61] J0.01 0.1 1 10 100 Favours [No int Nursing] Ird] Bidding of participants and personnel (performance bias) (C) Binding of participants and personnel (berformance bias) (C) Binding of participants and personnel (detection bias) (C) Binding of par	Study or Subgroup		Total	Events	Total	Weight	M-H, Random, 95% Cl	I M-H, Random, 95% CI	ABCDEFG
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1.1.1 Very satisfied v	with Quality of Life							
Pang2019 35 63 14 42 11.3% 2.50 [1.11, 5.63] Total events 315 96 Heterogeneity: Tax ² = 0.70; Chi ² = 13.47, df = 2 (P = 0.001); P = 85% Test for overall effect. Z = 2.66 (P = 0.002) 1.1.2 Satisfied with Quality of Life GouZ019 52 310 113 202 11.7% 0.16 [0.11, 0.24] Pang2019 52 310 113 42 11.3% 0.49 [0.22, 1.08] Pang2019 22 63 22 42 11.3% 0.49 [0.22, 1.08] Pang2019 22 0.03% 0.41 [0.13, 1.51] Total events 89 148 Heterogeneity: Tax ² = 1.07; Chi ² = 19.39, df = 2 (P < 0.0001); P = 90% Test for overall effect. Z = 3.1 (P = 0.19) 1.1.3 Dissatisfied with Quality of Life GouZ019 2 310 22 202 10.3% 0.05 [0.01, 0.23] Pang2019 6 6 63 6 42 10.7% 0.58 [0.16, 0.4, 0.59] Pang2019 6 6 63 6 42 10.7% 0.58 [0.16, 0.4, 0.59] Total events 11 42 45 858 100.0% 0.70 [0.19, 2.61] Total events 11 42 42 10.5% 0.15 [0.04, 0.59] Total events 415 226 Heterogeneity: Tax ² = 1.18; Chi ² = 7.11, df = 2 (P = 0.003); P = 72% Test for overall effect. Z = 2.31 (P = 0.02); P = 72% Test for overall effect. Z = 2.31 (P = 0.00); P = 85.9% Efficience: Chi ² = 1.41, df = 2 (P = 0.0008); P = 85.9% Efficience: Chi ² = 1.41, df = 2 (P = 0.0008); P = 85.9% Efficience: Chi ² = 1.41, df = 2 (P = 0.0008); P = 85.9% Efficience: Chi ² = 1.41, df = 2 (P = 0.0008); P = 85.9% Efficience: Chi ² = 1.41, df = 2 (P = 0.0008); P = 85.9% Efficience: Chi ² = 1.41, df = 2 (P = 0.0008); P = 85.9% Efficience: Chi ² = 1.41, df = 2 (P = 0.0008); P = 85.9% Efficience: Chi ² = 0.42; Chi ³ = 0.42; Chi ³ = 0.42; Chi ³ = 0.42; Chi ³ = 0.42;	Gou2019	256	310	67	202	11.7%	9.55 [6.31, 14.46]		
Subford (95% C) 1 14 5 286 34.2% 4.07 [1.45, 11.45] Table vents 315 96 derived and the coverall effect: Z = 2.66 (P = 0.001); P = 85% Test for overall effect: Z = 2.66 (P = 0.003) 11.2 Satisfied with Quality of Life Gou/2019 52 310 113 202 11.7% 0.16 [0.11, 0.24] J2020 15 42 13 42 11.2% 1.24 [0.50, 3.08] Subtoal (95% C) 415 286 34.2% 0.44 [0.13, 1.51] Table vents 89 1448 Heterogeneity: Tau" = 1.07; Chi" = 19.39, df = 2 (P < 0.0001); P = 90% Test for overall effect: Z = 1.31 (P = 0.19) 11.3 Dissatisfied with Quality of Life Gou/2019 2 310 22 202 10.3% 0.05 [0.01, 0.23] J2020 3 42 14 42 10.5% 0.15 [0.04, 0.57] Test for overall effect: Z = 1.31 (P = 0.19) 11.3 Dissatisfied with Quality of Life Gou/2019 2 310 22 202 10.3% 0.05 [0.01, 0.23] J2020 3 42 14 42 10.5% 0.15 [0.04, 0.57] Table vents 11 45 286 31.6% 0.18 [0.04, 0.77] Table vents 11 45 286 31.6% 0.18 [0.04, 0.77] Table vents 11 45 286 Heterogeneity: Tau" = 1.31; (Ph" = 7.11, df = 2 (P = 0.03); P = 72% Test for overall effect: Z = 0.31 (P = 2.218), df = 8 (P < 0.00001); P = 96% Test for overall effect: Z = 0.53 (P = 0.60) Test for subgroup differences: Chi" = 14.14, df = 2 (P = 0.0000); P = 8.5% Test for overall effect: Z = 0.53 (P = 0.60) Test for subgroup differences: Chi" = 14.14, df = 2 (P = 0.0000); P = 8.5% Test for overall effect: Z = 0.53 (P = 0.60) Test for subgroup differences: Chi" = 14.14, df = 2 (P = 0.0000); P = 8.5% Test for overall effect: Z = 0.53 (P = 0.60) Test for subgroup differences: Chi" = 14.14, df = 2 (P = 0.0000); P = 8.5% Test for overall effect: Z = 0.53 (P = 0.60) Test for subgroup differences: Chi" = 14.14, df = 2 (P = 0.0000); P = 8.5% Test for overall effect: Z = 0.53 (P = 0.60) Test for subgroup differences: Chi" = 14.14, df = 2 (P = 0.0000); P = 8.5% Test for overall effect: Z = 0.53 (P = 0.60) (B Michand on subcrone assessment (detectom bias) (C) Binding of patticipants and personnel (detectom bias) (C) Binding of patticipants and personnel (detectom bias) (C) Binding of patticipants a	Ji2020	24	42	15	42	11.2%	2.40 [1.00, 5.78]		
Total events 315 96 Heterogenely: Tau ² = 0.70, Chi ² = 13, 47, df = 2 (P = 0.001); P = 85% Test for overall effect Z = 2.86 (P = 0.008) 1.1.2 Satisfied with Quality of Life Gou2019 52 310 113 42 11.2% 0.46 [0.11, 0.24] Ju2020 15 42 13 42 11.2% 0.49 [0.22, 10.8] Output (95% C) 415 286 34.2% 0.44 [0.13, 1.51] Total events 89 148 Heterogenely: Tau ² = 1.07, Chi ² = 19.39, df = 2 (P < 0.0001); P = 90% Test for overall effect Z = -0.33 (P = 0.19) 1.1.3 Dissatisfied with Quality of Life Gou2019 2 310 22 202 10.3% 0.05 [0.01, 0.23] 1.1.3 Dissatisfied with Quality of Life Gou2019 2 310 22 202 10.3% 0.05 [0.01, 0.23] 1.1.3 Dissatisfied with Quality of Life Gou2019 2 310 22 202 10.3% 0.05 [0.01, 0.23] 1.1.3 Dissatisfied with Quality of Life Gou2019 2 310 22 202 10.3% 0.05 [0.01, 0.23] 1.1.3 Dissatisfied with Quality of Life Gou2019 2 314 42 10.5% 0.05 [0.04, 0.59] 1.2.4 [1.6; Chi ² - 7.1], df = 2 (P = 0.000; P = 72%) Total events 11 45 286 Heterogenely: Tau ² = 1.18; Chi ² - 7.11, df = 2 (P = 0.000; P = 72%) Test for overall effect Z = 0.53 (P = 0.00) Test for overall effect Z = 0.53 (P = 0.00) Test for overall effect Z = 0.53 (P = 0.00) Test for overall effect Z = 0.53 (P = 0.000) Test for overall effect Z = 0.53 (P = 0.000) Test for overall effect Z = 0.53 (P = 0.000) Childing of participants and personnel (performance bias) (B) Binding of participants and personnel (performance bias) (B) Binding of participants and personnel (performance bias) (C) Selective reporting (reporting tibes) (F) Selective reporting (reporting tibes) (F) Select	Pang2019	35	63	14	42	11.3%	2.50 [1.11, 5.63]		
Heterogeneity: Tay ² = 0.70; Chi ² = 13.47, df = 2 ($P = 0.001$); $P = 85\%$ Test for overall effect: Z = 2.66 ($P = 0.000$) 1.1.2 Satisfied with Quality of Life Gou2019 52 42 11.2% 0.16 [0.11, 0.24] J2020 15 42 13 42 11.2% 0.49 [0.22, 1.08] Subtoal (95% CI) 415 286 34.2% 0.44 [0.13, 1.51] Total events 89 148 Heterogeneity: Tay ² = 1.07; Chi ² = 19.39, df = 2 ($P < 0.0001$); $P = 90\%$ Test for overall effect: Z = 1.31 ($P = 0.19$) 1.1.3 Dissatisfied with Quality of Life Gou2019 2 310 22 202 10.3% 0.05 [0.01, 0.23] J2020 3 3 42 14 42 10.5% 0.15 [0.04, 0.59] Pang2019 6 63 6 42 10.7% 0.63 [0.19, 2.11] J2020 3 3 42 14 42 10.5% 0.65 [0.01, 0.23] J2020 3 3 42 14 42 10.5% 0.65 [0.01, 0.49] J2020 415 286 31.6% 0.15 [0.04, 0.59] Pang2019 6 63 6 42 10.7% 0.63 [0.19, 2.11] J2020 1 2 10 ($P = 0.02$) Total events 1 4 42 Heterogeneity: Tay ² = 1.18; Chi ² = 27.18, df = 2 ($P = 0.03$); $P = 72\%$ Test for overall effect: Z = 2.31 ($P = 0.02$) Total events 415 286 Heterogeneity: Tay ² = 3.81; Chi ² = 27.88, df = 8 ($P < 0.0006$); $P = 96\%$ Test for overall effect: Z = 0.53 ($P = 0.60$) Test for overall effect: Z = 0.53 ($P = 0.60$) Test for overall effect: Z = 0.53 ($P = 0.000$) Chail events 415 26 Heterogeneity: Tay ² = 3.81; Chi ² = 27.88, df = 8 ($P < 0.0006$); $P = 96\%$ Test for overall effect: Z = 0.53 ($P = 0.60$) Test for overall effect: Z = 0.53 ($P = 0.60$) Test for overall effect: Z = 0.53 ($P = 0.000$) (B) Alcadion concealment (selection bias) (B) Alcoration concealment (selection bias) (C) Binding of participants and personnet (derformance bias) (B) Alcoration concealment (selection bias) (C) Binding of participants and personnet (derformance bias) (C) Binding of	Subtotal (95% CI)		415		286	34.2%	4.07 [1.45, 11.45]		
Test for overall effect: $Z = 2.66 (P = 0.008)$ 1.1.2 Satisfied with Quality of Life Gau2019 52 310 113 202 11.7% 0.16 [0.11, 0.24] V_{2020} 15 42 13 42 11.2% 1.24 [0.50, 3.08] Pang2019 22 63 22 42 11.3% 0.49 [0.22, 1.08] Outboard (5% Cf) 415 286 34.2% Outboard (5% Cf) 61 2 310 22 202 10.3% 0.05 [0.01, 0.23] V_{2020} 3 42 14 42 10.5% 0.5 [0.04, 0.57] Pang2019 6 6 63 6 42 10.7% 0.63 [0.19, 2.11] Outboard (5% Cf) 415 286 31.6% Outboard (5% Cf) 415 286 31.6% Diabetral (5% Cf) 01 415 286 31.6% Diabetral (5% Cf) 01 415 286 31.6% Total events 415 20 (P = 0.0001); P = 97% Test for overall effect: $Z = 2.31 (P = 0.02)$; P = 72% Test for overall effect: $Z = 2.31 (P = 0.02)$; P = 72% Test for overall effect: $Z = 0.53 (P = 0.60)$ (B) Alchard for overall effect: $Z = 0.53 (P = 0.60)$ (B) Alchard for overall effect: $Z = 0.53 (P = 0.60)$ (B) Alchard for overall effect: $Z = 0.53 (P = 0.60)$ (C) Binding of partici	Total events	315		96					
Gou2019 52 310 113 202 11.7% 0.16 [0.11, 0.24] Jü2020 15 42 13 42 11.2% 1.24 [0.50, 3.08] Pang2019 22 63 22 42 11.3% 0.48 [0.22, 1.03] Subtotal (95% CI) 415 286 34.2% 0.44 [0.13, 1.51] Total events 89 148 Heterogenelity: Tau ² = 1.07; Chi ² = 19.39, df = 2 (P < 0.0001); i ² = 90% 0.05 [0.01, 0.23] Test for overall effect: Z = 1.31 (P = 0.19) 11.3 42 10.5% 0.15 [0.04, 0.59] Pang2019 6 63 6 42 10.7% 0.63 [0.19, 2.11] Valuetal (95% CI) 415 286 31.6% 0.18 [0.04, 0.77] Total events 11 42 42 42 10.7% 0.63 [0.19, 2.61] Test for overall effect: Z = 2.31 (P = 0.0000); i ² = 72% 286 31.6% 0.70 [0.19, 2.61] 0.01 0.1 0.01 0.01 0.01 100 Favours [Int Nursing Int] Test for overall effect: Z = 3.31; Chi ² = 2.788, df = 8 (P < 0.00001); i ² = 96% 785.9% 78.5% 78.5%				0.001); I ² = 85%					
Jd2020 15 42 13 42 11.2% 1.24 $[0.50, 3.08]$ Pang2019 22 63 22 42 11.3% 0.48 $[0.22, 1.08]$ Subtotal [95% CI) 415 286 34.2% 0.44 $[0.13, 1.51]$ Total events 89 148 Heterogeneity: Tau" = 1.07; Ch ² = 12.39, df = 2 (P < 0.0001); P = 90% Test for overall effect: Z = 1.31 (P = 0.19) 1.1.3 Dissatisfied with Quality of Life Gou2019 2 310 22 202 10.3% 0.05 $[0.01, 0.23]$ Pang2019 6 633 6 42 10.7% 0.63 $[0.19, 2.11]$ Subtotal [95% CI) 415 286 31.8% 0.15 $[0.04, 0.59]$ Pang2019 6 633 6 42 10.7% 0.63 $[0.19, 2.11]$ Subtotal [95% CI) 415 286 31.8% 0.15 $[0.04, 0.77]$ Total events 11 42 Heterogeneity: Tau" = 1.18; Ch ² = 7.11, df = 2 (P = 0.03); P = 72% Test for overall effect: Z = 2.31 (P = 0.02) Total events 415 286 Heterogeneity: Tau" = 3.81; Ch ² = 2.72, 88, df = 8 (P < 0.00001); P = 96% Test for overall effect: Z = 0.51 (P = 0.00) Test for subgroup differences: Chi ² = 14.14, df = 2 (P = 0.0008), P = 85.9% Risk of bias legend. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (C) Blinding of outcome data (attrition bias) (C) Selective reporting (reporting bias) (C) Other bias	1.1.2 Satisfied with 0	Quality of Life							
Jd2020 15 42 13 42 112% 12.4 $(0.50, 3.08]$ Pang2019 22 63 22 42 11.3% 0.49 $(0.22, 1.08]$ Subtotal [95% CI) 415 286 34.2% 0.44 $(0.13, 1.51]$ Total events 89 148 Heterogeneity: Tau" = 1.07; Ch ² = 12.39, dt 2 (P < 0.0001); P = 90% Test for overall effect: Z = 1.31 (P = 0.19) 1.1.3 Dissatisfied with Quality of Life Gou2019 2 310 22 202 10.3% 0.05 $[0.01, 0.23]$ J2020 3 42 14 42 10.5% 0.15 $[0.04, 0.59]$ Pang2019 6 6 3 6 42 10.7% 0.63 $[0.19, 2.11]$ Subtotal [95% CI) 415 286 31.6% 0.18 $[0.04, 0.57]$ Total events 11 42 Heterogeneity: Tau" = 1.18; Ch ² = 7.11, df = 2 (P = 0.03); P = 72% Test for overall effect: Z = 2.31 (P = 0.02) Total events 415 286 Heterogeneity: Tau" = 3.81; Ch ² = 7.21, df = 8 (P < 0.00001); P = 96% Test for overall effect: Z = 0.31 (P = 0.00) Test for subgroup differences: Ch ² = 14.14, df = 2 (P = 0.0008), P = 85.9% Risk of bias legend. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (C) Blinding of outcome data (attrition bias) (C) Blinding of outcome data (attrition bias) (C) Selective reporting (reporting bias) (C) Other bias	Gou2019	52	310	113	202	11.7%	0.16 [0.11, 0.24]		
Pang2019 22 63 22 42 11.3% $0.49[0.22, 1.08]$ Subtotal (95% CI) 415 286 34.2% $0.44[0.13, 1.51]$ Heterogeneity: Tau" = 1.07; Chi ² = 19.39; df = 2 ($P < 0.0001$); $P = 90\%$ Test for overall effect: Z = 1.31 ($P = 0.19$) 1.1.3 Dissatisfied with Quality of Life Gou2019 2 310 22 202 10.3% $0.05[0.01, 0.23]$ Pang2019 6 63 6 42 10.7% $0.68[0.19, 2.11]$ Subtotal (95% CI) 415 286 31.6% $0.15[0.04, 0.59]$ Pang2019 6 63 6 42 10.7% $0.68[0.19, 2.11]$ Total events 11 42 Heterogeneity: Tau" = 1.18; Chi ² = 7.11, df = 2 ($P = 0.00001$); $P = 72\%$ Test for overall effect: Z = 2.31 ($P = 0.03$); $P = 72\%$ Test for overall effect: Z = 2.31 ($P = 0.03$); $P = 72\%$ Test for overall effect: Z = 0.53 ($P = 0.60$) Test for subgroup differences: Chi ² = 14.14, df = 2 ($P = 0.00001$); $P = 85.9\%$ Risk of bias legand. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (C) Blinding of outcome data (attrition bias) (C) Blinding of outcome data (attrition bias) (C) Blinding of outcome data (attrition bias) (C) Selective reporting (reporting bias) (G) Other bias									
SubTotal (95% CI) 415 286 34.2% 0.44 $[0.13, 1.51]$ Total events 89 148 Heterogeneity: Tau" = 10.7; Chi" = 19.39, df = 2 (P < 0.0001); I" = 90%	Pang2019								
Heterogeneity: Tau ² = 1.07; Chi ² = 19.39, df = 2 (P < 0.0001); l ² = 90% Test for overall effect: $Z = 1.31$ (P = 0.19) 1.1.3 Dissatisfied with Quality of Life Gou2019 2 310 22 202 10.3% 0.05 [0.01, 0.23] Ji2020 3 42 14 42 10.5% 0.15 [0.04, 0.59] Pang2019 6 633 6 42 10.7% 0.63 [0.19, 2.11] Subtoal (95% Cl) 415 286 31.6% 0.18 [0.04, 0.77] Total events 11 42 Heterogeneity: Tau ² = 1.18; Chi ² = 7.11, df = 2 (P = 0.03); l ² = 72% Test for overall effect: $Z = 2.31$ (P = 0.02) Total events 415 286 Heterogeneity: Tau ² = 3.81; Chi ² = 27.88, df = 8 (P < 0.00001); l ² = 96% Test for overall effect: $Z = 0.53$ (P = 0.60) Test for overall efferences: Chi ² = 14.14, df = 2 (P = 0.0008), l ² = 85.9% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Elinding of outcome assessment (detection bias) (C) Blinding of outcome assessment (detection bias) (C) Blinding of outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias	Subtotal (95% CI)								
Heterogeneity: Tau ² = 1.07; Chi ² = 19.39, df = 2 (P < 0.0001); l ² = 90% Test for overall effect: $Z = 1.31$ (P = 0.19) 1.1.3 Dissatisfied with Quality of Life Gou2019 2 310 22 202 10.3% 0.05 [0.01, 0.23] Ji2020 3 42 14 42 10.5% 0.15 [0.04, 0.59] Pang2019 6 633 6 42 10.7% 0.63 [0.19, 2.11] Subtoal (95% Cl) 415 286 31.6% 0.18 [0.04, 0.77] Total events 11 42 Heterogeneity: Tau ² = 1.18; Chi ² = 7.11, df = 2 (P = 0.03); l ² = 72% Test for overall effect: $Z = 2.31$ (P = 0.02) Total events 415 286 Heterogeneity: Tau ² = 3.81; Chi ² = 27.88, df = 8 (P < 0.00001); l ² = 96% Test for overall effect: $Z = 0.53$ (P = 0.60) Test for overall efferences: Chi ² = 14.14, df = 2 (P = 0.0008), l ² = 85.9% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Elinding of outcome assessment (detection bias) (C) Blinding of outcome assessment (detection bias) (C) Blinding of outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias	Total events	89		148				-	
Gou2019 2 310 22 202 10.3% $0.05 [0.01, 0.23]$ Ji2020 3 42 14 42 10.5% $0.15 [0.04, 0.59]$ Subtotal (95% CI) 415 286 31.6% $0.63 [0.19, 2.11]$ Subtotal (95% CI) 415 286 31.6% $0.18 [0.04, 0.77]$ Total events 11 42 Heterogeneity: Tau ² = 1.18; Chi ² = 7.11, df = 2 (P = 0.03); l ² = 72% Test for overall effect: Z = 2.31 (P = 0.02) Total events 415 286 Heterogeneity: Tau ² = 3.81; Chi ² = 227.88, df = 8 (P < 0.00001); l ² = 96% Test for overall effect: Z = 0.53 (P = 0.60) Test for overall effect: Z = 0.53 (P = 0.60) Test for overall effect: Z = 0.53 (P = 0.60) Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias)			df = 2 (P <	0.0001); l ² = 909	6				
Ji2020 3 42 14 42 10.5% 0.15 [0.04, 0.59] Pang2019 6 63 6 42 10.7% 0.63 [0.19, 2.11] Subtotal (95% CI) 415 286 31.6% 0.18 [0.04, 0.77] Total events 11 42 Heterogeneity: Tau ² = 1.18; Chi ² = 7.11, df = 2 (P = 0.03); I ² = 72% Total events 415 286 Heterogeneity: Tau ² = 3.81; Chi ² = 227.88, df = 8 (P < 0.00001); I ² = 96% Test for overall effect: Z = 0.53 (P = 0.60) Test for subgroup differences: Chi ² = 14.14, df = 2 (P = 0.008), I ² = 85.9% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (C) Blinding of participants and personnel (performance bias) (C) Blinding of participants and personnel (performance bias) (F) Selective reporting (reporting bias) (G) Other bias	1.1.3 Dissatisfied with	th Quality of Life							
Ji2020 3 42 14 42 10.5% 0.15 [0.04, 0.59] Pang2019 6 63 6 42 10.7% 0.63 [0.19, 2.11] Subtotal (95% CI) 415 286 31.6% 0.18 [0.04, 0.77] Total events 11 42 Heterogeneity: Tau ² = 1.18; Chi ² = 7.11, df = 2 (P = 0.03); I ² = 72% Test for overall effect: Z = 2.31 (P = 0.02) Total events 415 286 Heterogeneity: Tau ² = 3.81; Chi ² = 227.88, df = 8 (P < 0.00001); I ² = 96% Test for overall effect: Z = 0.53 (P = 0.60) Test for subgroup differences: Chi ² = 14.14, df = 2 (P = 0.008), I ² = 85.9% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (B) Allocation concealsent (detection bias) (C) Blinding of participants and personnel (performance bias) (C) Blinding of participants and personnel (performance bias) (C) Blinding of participants and personnel (performance bias) (F) Selective reporting (reporting bias) (G) Other bias	Gou2019	2	310	22	202	10.3%	0.05 [0.01, 0.23]		
Subtotal (95% CI) 415 286 31.6% 0.18 [$0.04, 0.77$] Total events 11 42 Heterogeneity: Tau ² = 1.18; Chi ² = 7.11, df = 2 (P = 0.03); I ² = 72% Test for overall effect: Z = 2.31 (P = 0.02) Total events 415 Total events 415 Coverall effect: Z = 2.31 (P = 0.02) Total events 415 Total events 415 Subtotal events 415 Total events 415 Total events 415 Total events 415 Total events 415 Risk of bias legend (0.10, 0.1, 0.1, 0.1, 0.1, 0.1, 0.1, 0.1,	Ji2020	3	42	14	42	10.5%	0.15 [0.04, 0.59]		
Total events 11 42 Heterogeneity: Tau ² = 1.18; Chi ² = 7.11, df = 2 (P = 0.03); I ² = 72% Test for overall effect: Z = 2.31 (P = 0.02) Total events 415 286 Heterogeneity: Tau ² = 3.81; Chi ² = 227.88, df = 8 (P < 0.00001); I ² = 96% Test for overall effect: Z = 0.53 (P = 0.60) Test for subgroup differences: Chi ² = 14.14, df = 2 (P = 0.0008), I ² = 85.9% <u>Risk of bias legend</u> (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (F) Selective reporting (reporting bias) (G) Other bias	Pang2019	6	63	6	42	10.7%	0.63 [0.19, 2.11]		
Heterogeneity: Tau ² = 1.18; Chi ² = 7.11, df = 2 (P = 0.03); l ² = 72% Test for overall effect: Z = 2.31 (P = 0.02) Total (95% Cl) 1245 858 100.0% 0.70 [0.19, 2.61] Total events 415 286 Heterogeneity: Tau ² = 3.81; Chi ² = 227.88, df = 8 (P < 0.00001); l ² = 96% Test for overall effect: Z = 0.53 (P = 0.60) Test for overall effect: Z = 0.53 (P = 0.60) Test for subgroup differences: Chi ² = 14.14, df = 2 (P = 0.0008), l ² = 85.9% <u>Risk of bias legend</u> (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (B) Allocation conceal ad (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias	Subtotal (95% CI)		415		286	31.6%	0.18 [0.04, 0.77]		
Test for overall effect: $Z = 2.31 (P = 0.02)$ Total (95% CI)1245858100.0%0.70 [0.19, 2.61]Total events415286Heterogeneity: Tau ² = 3.81; Chi ² = 227.88, df = 8 (P < 0.00001); I ² = 96%Test for subgroup differences: Chi ² = 1.41, df = 2 (P = 0.0008), I ² = 85.9%Risk of bias legend(A) Random sequence generation (selection bias)(B) Allocation concealment (selection bias)(C) Blinding of participants and personnel (performance bias)(D) Blinding of outcome data (attrition bias)(F) selective reporting (reporting bias)(G) Other bias	Total events	11		42					
Total events 415 286 Heterogeneity: Tau ² = 3.81; Chi ² = 227.88, df = 8 (P < 0.00001); I ² = 96% 10.01 0.1 100 Test for overall effect: Z = 0.53 (P = 0.60) Favours [No int Nursing] Favours [Int Nursing Int] Test for subgroup differences: Chi ² = 14.14, df = 2 (P = 0.0008), I ² = 85.9% Favours [No int Nursing] Favours [Int Nursing Int] (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) Favours [Int Nursing Int] (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (B) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias			f = 2 (P = 0	0.03); I² = 72%					
Heterogeneity: Tau ² = 3.81; Chi ² = 227.88, df = 8 (P < 0.00001); l ² = 96% 0.01 0.01 0.1 10 100 Test for overall effect: Z = 0.53 (P = 0.60) Favours [No int Nursing] Favours [Int Nursing Int] Test for subgroup differences: Chi ² = 14.14, df = 2 (P = 0.0008), l ² = 85.9% Favours [No int Nursing] Favours [Int Nursing Int] (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (B) Blinding of participants and personnel (performance bias) (C) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrittion bias) (F) Selective reporting (reporting bias) (G) Other bias (G) Other bias (F) Selective reporting (reporting bias)	Total (95% CI)		1245		858	100.0%	0.70 [0.19, 2.61]		
Test for overall effect: Z = 0.53 (P = 0.60) 0.01	Total events	415		286					
Test for overall effect: Z = 0.53 (P = 0.60) Test for subgroup differences: Chi ² = 14.14, df = 2 (P = 0.0008), l ² = 85.9% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias	Heterogeneity: Tau ² =	= 3.81; Chi ² = 227.88,	df = 8 (P	< 0.00001); l ² = 9	6%				<u> </u>
Test for subgroup differences: Chi ² = 14.14, df = 2 (P = 0.0008), l ² = 85.9% <u>Risk of bias legend</u> (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias	Test for overall effect:	Z = 0.53 (P = 0.60)							
(A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias	Test for subgroup diffe	erences: Chi ² = 14.14	4, df = 2 (F	P = 0.0008), I ² = 8	5.9%				ing
(B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias	Risk of bias legend								
(C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias	(A) Random sequence	e generation (selection	on bias)						
 (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias 	(B) Allocation conceal	Iment (selection bias))						
 (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other bias 	(C) Blinding of particip	pants and personnel	, (performar	nce bias)					
(F) Selective reporting (reporting bias) (G) Other bias	(D) Blinding of outcom	ne assessment (deter	 ction bias)						
(G) Other bias	(E) Incomplete outcon	ne data (attrition bias)						
	(F) Selective reporting								
	(-)	Figure 2 Imm	roveme	nt in quality	of life :	followin	a intense nursina a	care among patients with liver cano	ers

significantly better in those patients who received intensive nursing care.

A study analyzing the effects of comprehensive nursing care applied in interventional therapy for patients with liver cancer showed that the degree of great satisfaction among the patients was with comprehensive nursing care indicating that the latter was superior compared to the conventional nursing care further supporting the results of this current analysis.^[8]

In another study^[9] based on the efficacy of high quality nursing on alleviating adverse reactions and cancer pain and its effect on quality of life of patients with liver cancer after interventional surgery, the authors demonstrated that this can decrease hospitalization following surgery, improve appetite and sleep quality as well as reduce pain and other post-operative adverse effects. The authors also concluded that the quality of life was significantly improved, further supporting the results of this current analysis.


	Int Nursir	Int Nursing Intervention No Int Nursing Interv						Mean Difference	Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
2.1.1 Self rating Anxi	ety Score									
Li2018	30.98	5.33	52	36.87	4.29	52	12.7%	-5.89 [-7.75, -4.03]		
Luan2020	41.7	4.25	200	48.92	5.05	200	23.9%	-7.22 [-8.13, -6.31]		
Pang2019	40.54	3.6	63	50.83	6.9	42	9.8%	-10.29 [-12.56, -8.02]	+	
Subtotal (95% CI)			315			294	46.5%	-7.66 [-9.66, -5.66]	•	
Heterogeneity: Tau ² =	2.38; Chi ² = 8	8.90, df = 2	2 (P = 0.0	1); l ² = 78	%					
Test for overall effect:	Z = 7.50 (P <	: 0.00001)								
2.1.2 Self rating Depr										
Li2018	31.56	4.38	52	38.76	3.85	52	15.3%	-7.20 [-8.79, -5.61]		
Luan2020	40.61	2.8	200	48.65	3.86	200	27.6%	-8.04 [-8.70, -7.38]	•	
Pang2019	43.23	3.8	63	50.17	6.4	42	10.5%	-6.94 [-9.09, -4.79]		
Subtotal (95% CI)			315			294	53.5%	-7.84 [-8.43, -7.26]		
Heterogeneity: Tau ² =				4); l ² = 0%	Ď					
Test for overall effect:	Z = 26.19 (P	< 0.00001)							
Total (95% CI)			630			588	100.0%	-7.55 [-8.39, -6.70]	+	
Heterogeneity: Tau ² =	0.56; Chi ² =	11.56, df =	5 (P = 0.	.04); l ² = 5	7%				-100 -50 0 50	
Test for overall effect:	Z = 17.50 (P	< 0.00001)						-100 -50 0 50 Favours [Int nursing Int] Favours [No	
Test for subgroup diffe	rences: Chi2	= 0.03, df	= 1 (P = (0.86), I² =	0%					int Nursing]
Risk of bias legend										
(A) Random sequence	generation (selection b	oias)							
(B) Allocation conceal	ment (selectio	on bias)								
(C) Blinding of particip	ants and pers	sonnel (per	formance	e bias)						
(D) Blinding of outcom	e assessmer	nt (detectio	n bias)							
(E) Incomplete outcom	e data (attriti	on bias)	,							
(F) Selective reporting	(reporting bia	as)								
(G) Other bias										

Figure 3. Improvement in self-rating anxiety and depression scales following intense nursing care in patients with liver cancers.

	Int Nursi	ng Interve	ntion	No Int N	lursing l	nterv		Mean Difference	Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	ABCDEFG
2.1.1 Physical function	ı									
Gou2019	83.01	7.55	310	69.52	9.52	202	14.3%	13.49 [11.93, 15.05]		
li2020	72.87	3.94	42	59.21	4.4	42	14.3%	13.66 [11.87, 15.45]		
Subtotal (95% CI)			352			244	28.7%	13.56 [12.39, 14.74]	+	
Heterogeneity: Tau ² = 0	.00; Chi² =	0.02, df = 1	I (P = 0.8	9); l² = 0%	ó					
Fest for overall effect: Z	= 22.63 (P	< 0.00001)							
2.1.2 Social function										
Gou2019	88.64	7.03	310	70.68	9.35	202	14.4%	17.96 [16.45, 19.47]		
li2020	77.63	8.33	42	63.43	9.4	42	14.0%	14.20 [10.40, 18.00]	-	
uan2020	1.29	0.15	200	0.82	0.23	200	14.4%	0.47 [0.43, 0.51]	+	
Subtotal (95% CI)			552			444	42.8%	10.84 [-2.83, 24.51]	◆	
Heterogeneity: Tau ² = 1			df = 2 (P	< 0.00001); I ² = 10	0%				
Fest for overall effect: Z	= 1.55 (P =	= 0.12)								
1.3 Activity score										
Gou2019	88.64	7.03	310	70.68	9.35	202	14.4%	17.96 [16.45, 19.47]		
Pang2019	63.45	5.66	63	48.65	7.52	42	14.2%	14.80 [12.13, 17.47]		
Subtotal (95% CI)			373			244	28.6%	16.58 [13.51, 19.65]	•	
Heterogeneity: Tau ² = 3 Test for overall effect: Z				4); l² = 75	%					
Total (95% CI)			1277			932	100.0%	13.20 [5.07, 21.34]	•	
Heterogeneity: Tau ² = 1	19.40; Chi ²	= 1667.15	, df = 6 (F	o < 0.0000	1); l ² = 1	00%			-100 -50 0 50	100
Fest for overall effect: Z	= 3.18 (P =	= 0.001)							Favours [No nursing Int] Favours [Int Nursing	
Test for subgroup different	ences: Chi ²	= 3.43, df	= 2 (P = 0	0.18), I ² =	41.7%				avours [no hursing mg - r avours [mt hursin	ig ing
Risk of bias legend										
A) Random sequence	generation (selection b	oias)							
B) Allocation concealm	ent (selection	on bias)								
c) Blinding of participal	nts and pers	sonnel (per	formance	e bias)						
D) Blinding of outcome	assessmer	nt (detectio	n bias)	,						
E) Incomplete outcome			,							
F) Selective reporting (
G) Other bias	oporting bi	,								
e, etter 5.00										
									ng care in patients with liver cand	

The potential reasons to support an intensive nursing care could be related to the fact that health education could be enhanced, and a reduction in uncertainty about the disease was assured. An intensive nursing care could also be valuable in terms of helping the patients to look for information and motivations related to the potential cure of their disease.^[16] Intensive nursing care also included immediate reporting of symptoms and any abnormal report para and post operatively to the concerned physicians which might lead to a fast response, and a rapid treatment so as to avoid complications, and to improve prognosis among the patients.^[17]

At last, intensive nursing care is a new nursing model, which might have significant clinical implication in the future among patients with liver cancer requiring surgical intervention.



4.1. Limitations

The limitations were: due to the publication of only a few original research articles based on nursing care in patients with liver cancers, our analysis included only a limited number of participants. In addition, due to the involvement of only a few studies, data analysis was carried out on subgroups with the inclusion of only 2 or 3 studies in most of the cases. Another limitation could be the fact that data were retrieved from studies which were mainly observational cohorts, which might have been the cause for this high level of heterogeneity among several subgroups assessing corresponding outcomes. In addition, several relevant outcomes were reported only in 1 study, and were unable to be assessed due to a lack of study data for comparison.

5. Conclusions

Our current analysis showed that intense nursing care significantly improved anxiety, depression, and quality of life following interventions in patients with liver cancers. Most of the patients with liver cancers who were assigned to an intense nursing care were very satisfied with their quality of life. However, this hypothesis should further be confirmed in larger nursing related studies based on patients with liver cancers.

Author contributions

The authors QZ, RW and CL were responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. QZ and RW are the first coauthors and they wrote this manuscript. All the authors agreed and approved the manuscript as it is. Conceptualization: Qiao Zhang, Rong Wan, Changdan Liu. Data curation: Qiao Zhang, Rong Wan, Changdan Liu. Formal analysis: Qiao Zhang, Rong Wan, Changdan Liu. Funding acquisition: Qiao Zhang, Rong Wan, Changdan Liu. Investigation: Qiao Zhang, Rong Wan, Changdan Liu. Methodology: Qiao Zhang, Rong Wan, Changdan Liu. Project administration: Qiao Zhang, Rong Wan, Changdan Liu. Resources: Qiao Zhang, Rong Wan, Changdan Liu. Software: Qiao Zhang, Rong Wan, Changdan Liu. Supervision: Qiao Zhang, Rong Wan, Changdan Liu. Validation: Qiao Zhang, Rong Wan, Changdan Liu. Visualization: Qiao Zhang, Rong Wan, Changdan Liu. Writing – original draft: Qiao Zhang, Rong Wan. Writing – review & editing: Qiao Zhang, Rong Wan.

References

- Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499:97–101.
- [2] Sha M, Seogsong J, Xia Q. Liver transplantation for cirrhotic patients with small cholangiocarcinoma: what are the optimal criteria? Liver Transpl 2020.
- [3] Gentry SE, Segev DL. Restructuring the Organ Procurement and Transplantation Network contract to achieve policy coherence and infrastructure excellence. Am J Transplant 2019;19:1622–7.
- [4] Hasselgren K, Isaksson B, Ardnor B, et al. Liver resection is beneficial for patients with colorectal liver metastases and extrahepatic disease. Ann Transl Med 2020;8:109.
- [5] Rashidian N, Willaert W, Van Herzeele I, et al. FULCRUM Research Group. Key components of a hepatobiliary surgery curriculum for general surgery residents: results of the FULCRUM International Delphi consensus. HPB (Oxford) 2020;Feb 11;S1365-182X(20)30030-7.
- [6] Hunt L. Advanced nurse practitioners may have general surgery role. Emerg Nurse 2016;24:8–9.

- [7] Jennings FL, Mitchell M. Intensive care nurses' perceptions of Inter Specialty Trauma Nursing Rounds to improve trauma patient care-A quality improvement project. Intensive Crit Care Nurs 2017;40: 35–43.
- [8] Gou Y, Yi J, Jiang M, et al. Analysis on effects of comprehensive nursing care applied in interventional therapy for patients with liver cirrhosis and liver cancer. Iran J Public Health 2019;48:494–500.
- [9] Jing J, Long S, Guoyun Z, et al. A study on the efficacy of high-quality nursing on alleviating adverse reactions and cancer pain, and its effect on QOL of patients with liver cancer after interventional surgery. Int J Clin Exp Med 2020;13:925–32.
- [10] Shengchao Li, Ye Zhou. Influence of individual nursing care on postoperative early recovery and negative emotions in primary liver cancer patients. Int J Clin Exp Med 2018;11:4702–8.
- [11] Luan L, Wang L. Observation of nursing effect for patients with primary liver cancer before and after transcatheter arterial embolization. Pak J Pharm Sci 2019;32:2455–8.
- [12] Pang L, Wang Y, Xing Y, et al. Application effects of whole course highquality nursing on patients with liver cancer during radiotherapy. Iran J Public Health 2019;48:1777–85.
- [13] Higgins JP, Altman DG, Higgins JP, et al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
- [14] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
- [15] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339: b2700.
- [16] Kmiecik J, Poli A, Brons NH, et al. Elevated CD3+ and CD8+ tumorinfiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol 2013;264:71–83.
- [17] Pires NM, Dong T, Hanke U, Hoivik N. Integrated optical microfluidic biosensor using a polycarbazole photodetector for point-of-care detection of hormonal compounds. J Biomed Opt 2013;18:097001.